BREAKING NEWS
Cloud Server Hosting For Online Businesses
Inexpensive SEO Services
Benefits of Wanting to play Free Online Slot machines
Sinopharm CNBG COVID-19 vaccine

Summary

Sinopharm NVSI COVID-19 vaccine, also known as mutI-tri-RBD or NVSI-06-08, is a COVID-19 vaccine developed by National Vaccine & Serum Institute (NVSI, 中生研究院), a subsidiary of CNBG of Sinopharm.[1][2]

Sinopharm CNBG COVID-19 vaccine
Vaccine description
TargetSARS-CoV-2
Vaccine typeProtein subunit
Clinical data
Routes of
administration		Intramuscular
Legal status
Legal status

They claim to be the world's first "second generation broadly protective" recombination protein subunit vaccine, i.e. by combining three heterogeneous antigens into one single trimer RBD protein (突变集成三聚化RBD, mutI-tri-RBD).[3] It's based on the original, and the Beta (K417N/E484K/N501Y) and Kappa (L452R/E484K) variants.[4]

References edit

  1. ^ "Emergency use of Sinopharm's new CNBG protein vaccine approved in UAE". Gulf News. 27 December 2021. Retrieved 27 December 2021.
  2. ^ "China's new recombinant COVID-19 vaccine starts human tests". Xinhua. 25 April 2021. Retrieved 5 May 2021.
  3. ^ 國藥集團：二代重組蛋白新冠疫苗保護效果良好
  4. ^ Kaabi NA, Yang YK, Du LF, Xu K, Shao S, Liang Y, et al. (June 2022). "Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial". Nature Communications. 13 (1): 3654. Bibcode:2022NatCo..13.3654K. doi:10.1038/s41467-022-31379-0. PMC 9237056. PMID 35760812.
 
Scholia has a profile for Sinopharm CNBG COVID-19 vaccine (Q110291641).